Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 11
Submit an article Journal homepage
324
Views
61
CrossRef citations to date
0
Altmetric
Review

Pharmacological treatment of nephropathic cystinosis with cysteamine

Robert Kleta NHGRI, Building 10, Room 10C-107, MSC 1851, 10 Center Drive, Bethesda, MD 20892, USA. [email protected]
&
William A Gahl National Institutes of Health, Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, USA
Pages 2255-2262 | Published online: 25 Feb 2005

Citations (61)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Enriko Klootwijk, Stephanie Dufek, Naomi Issler, Detlef Bockenhauer & Robert Kleta. (2017) Pathophysiology, current treatments and future targets in hereditary forms of renal Fanconi syndrome. Expert Opinion on Orphan Drugs 5:1, pages 45-54.
Read now
Gregory M Pastores & Natalie L Barnett. (2005) Current and emerging therapies for the lysosomal storage disorders. Expert Opinion on Emerging Drugs 10:4, pages 891-902.
Read now

Articles from other publishers (59)

Brian K. Lee & Christie P. Thomas. (2024) Genetic testing in the evaluation of recipient candidates and living kidney donors. Current Opinion in Nephrology & Hypertension 33:1, pages 4-12.
Crossref
Anna Luiza Braga Albuquerque, Rafael dos Santos Borges, Ana Flávia Conegundes, Erika Emmylaine dos Santos, Frederico Moreira Man Fu, Clara Tavares Araujo, Pedro Alves Soares Vaz de Castro & Ana Cristina Simões e Silva. (2023) Inherited Fanconi syndrome. World Journal of Pediatrics 19:7, pages 619-634.
Crossref
Leonie Keidel, Katharina Hohenfellner, Benedikt Schworm, Siegfried Priglinger, Nikolaus Luft & Claudia Priglinger. (2023) Spectral domain optical coherence tomography-based retinochoroidal cystine crystal score: a window into infantile nephropathic cystinosis. British Journal of Ophthalmology 107:2, pages 234-241.
Crossref
Trevor F. Killeen, Sarah L. Elfering, Samy M. Riad, Michael A. Linden, Ethan Y. Leng, Raja Kandaswamy, Sarah J. Kizilbash, Blanche M. Chavers & James V. Harmon. (2022) Nephropathic cystinosis in a kidney transplant recipient: A mesenteric lymph node demonstrates positive birefringent crystals. Human Pathology Reports 29, pages 300661.
Crossref
Li Zhou, Tiejian Li, Ying Sun, Hongwu Tian, Cunxiu Gao, Chunli Liu, Lingli Kong, Guimin Zhang & Tiesheng Shi. (2020) Mechanistic scrutiny of the oxidations of thiol‐containing drugs cysteamine and d ‐penicillamine by cis ‐diamminetetrachloroplatinum(IV) . International Journal of Chemical Kinetics 53:4, pages 548-557.
Crossref
Katharina Hohenfellner & Jens Deerberg-Wittram. (2020) Coordinated, Cost-effective Care for Rare Disease: The Cystinosis Outpatient Consultation Program at RoMed. NEJM Catalyst 1:4.
Crossref
Angelina Magreni Dixon, Courtney Styres & Caroline Straatmann. (2020) An Infant With Vomiting, Constipation, and Weight Loss. Clinical Pediatrics 59:6, pages 629-632.
Crossref
Ivana Palucci, Giuseppe Maulucci, Flavio De Maio, Michela Sali, Alessandra Romagnoli, Linda Petrone, Gian Maria Fimia, Maurizio Sanguinetti, Delia Goletti, Marco De Spirito, Mauro Piacentini & Giovanni Delogu. (2020) Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis. Frontiers in Immunology 10.
Crossref
Hongnan Liu, Miaomiao Bai, Bie Tan, Kang Xu, Rong Yu, Ruilin Huang & Yulong Yin. (2019) Influence of supplemented coated-cysteamine on morphology, apoptosis and oxidative stress status of gastrointestinal tract. BMC Veterinary Research 15:1.
Crossref
F. Cicchetti, L.S. David, A. Siddu & H.L. Denis. (2019) Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial. Neurobiology of Disease 130, pages 104530.
Crossref
John W. Foreman. (2019) Fanconi Syndrome. Pediatric Clinics of North America 66:1, pages 159-167.
Crossref
Danielle Armas, Robert J. Holt, Nils F. Confer, Gregg C. Checani, Mohammad Obaidi, Yuli Xie & Meg Brannagan. (2018) A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. Advances in Therapy 35:2, pages 199-209.
Crossref
Katherine A. Lyseng-Williamson. (2017) Cystadrops® (cysteamine hydrochloride 0.55% viscous eye-drops solution) in treating corneal cystine crystal deposits in patients with cystinosis: a profile of its use. Drugs & Therapy Perspectives 33:5, pages 195-201.
Crossref
Neda Moradin, Sabrina Torre, Susan Gauthier, Mifong Tam, Jalal Hawari, Kirsten Vandercruyssen, Bart De Spiegeleer, Anny Fortin, Mary M. Stevenson & Philippe Gros. (2016) Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria. Malaria Journal 15:1.
Crossref
Mike Kalogiannis, E. James Delikatny & Thomas M. Jeitner. (2016) Serotonin as a putative scavenger of hypohalous acid in the brain. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1862:4, pages 651-661.
Crossref
Allison Berryhill, Suvarna Bhamre, Abanti Chaudhuri, Waldo Concepcion & Paul C. Grimm. (2015) Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re‐initiation of cysteamine therapy during the immediate post‐transplant period. Pediatric Transplantation 20:1, pages 141-145.
Crossref
Raymond Quigley & Matthias T. F. Wolf. 2016. Pediatric Nephrology. Pediatric Nephrology 1273 1306 .
John Foreman. (2015) Genetic Diseases of the Kidney. The Open Urology & Nephrology Journal 8:1, pages 136-147.
Crossref
Barbara McKenzie, Graeme Kay, Kerr H. Matthews, Rachel M. Knott & Donald Cairns. (2015) The hen’s egg chorioallantoic membrane (HET-CAM) test to predict the ophthalmic irritation potential of a cysteamine-containing gel: Quantification using Photoshop® and ImageJ. International Journal of Pharmaceutics 490:1-2, pages 1-8.
Crossref
Galina Nesterova, Caitlyn Williams, Isa Bernardini & William A. Gahl. (2014) Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy. Pediatric Nephrology 30:6, pages 945-951.
Crossref
G. Ariceta, E. Lara, J. A. Camacho, F. Oppenheimer, J. Vara, F. Santos, M. A. Munoz, C. Cantarell, M. Gil Calvo, R. Romero, B. Valenciano, V. Garcia-Nieto, M. J. Sanahuja, J. Crespo, M. L. Justa, A. Urisarri, R. Bedoya, A. Bueno, A. Daza, J. Bravo, F. Llamas & L. A. Jimenez del Cerro. (2014) Cysteamine (Cystagon(R)) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. Nephrology Dialysis Transplantation 30:3, pages 475-480.
Crossref
Pierre Kaminsky & Olivier Lidove. (2014) Stratégies thérapeutiques actuelles dans les maladies lysosomales. La Presse Médicale 43:11, pages 1174-1184.
Crossref
Philip J Brooks, Danilo A Tagle & Steve Groft. (2014) Expanding rare disease drug trials based on shared molecular etiology. Nature Biotechnology 32:6, pages 515-518.
Crossref
Raymond Quigley & Matthias T. F. Wolf. 2014. Pediatric Nephrology. Pediatric Nephrology 1 40 .
M. Alfadhel, K. Al-Thihli, H. Moubayed, W. Eyaid & M. Al-Jeraisy. (2013) Drug treatment of inborn errors of metabolism: a systematic review. Archives of Disease in Childhood 98:6, pages 454-461.
Crossref
C. N. Harvey-Woodworth. (2013) Dimethylsulphidemia: the significance of dimethyl sulphide in extra-oral, blood borne halitosis. British Dental Journal 214:7, pages E20-E20.
Crossref
Ranjan Dohil & Patrice Rioux. (2013) Pharmacokinetic Studies of Cysteamine Bitartrate Delayed‐Release. Clinical Pharmacology in Drug Development 2:2, pages 178-185.
Crossref
Galina Nesterova & William A. Gahl. (2012) Cystinosis: the evolution of a treatable disease. Pediatric Nephrology 28:1, pages 51-59.
Crossref
Dimitrios Tsikas, Christopher E. Evans, Travis T. Denton, Anja Mitschke, Frank-Mathias Gutzki, John T. Pinto, Tetyana Khomenko, Sandor Szabo & Arthur J.L. Cooper. (2012) Stable isotope gas chromatography–tandem mass spectrometry determination of aminoethylcysteine ketimine decarboxylated dimer in biological samples. Analytical Biochemistry 430:1, pages 4-15.
Crossref
Ranjan Dohil, Betty L. Cabrera, Jon Gangoiti & Patrice Rioux. (2013) The Effect of Food on Cysteamine Bitartrate Absorption in Healthy Participants. Clinical Pharmacology in Drug Development 1:4, pages 170-174.
Crossref
Barbara Buchan, Graeme Kay, Kerr H. Matthews & Donald Cairns. (2012) Suppository formulations as a potential treatment for nephropathic cystinosis. Journal of Pharmaceutical Sciences 101:10, pages 3729-3738.
Crossref
Ranjan Dohil, Alison Carrigg & Robert Newbury. (2012) A Potential New Method to Estimate Tissue Cystine Content in Nephropathic Cystinosis. The Journal of Pediatrics 161:3, pages 531-535.e1.
Crossref
Stephen Niemiec, Angela Ballantyne & Doris A. Trauner. (2012) Cognition in nephropathic cystinosis: Pattern of expression in heterozygous carriers. American Journal of Medical Genetics Part A 158A:8, pages 1902-1908.
Crossref
Toshio Fujisawa, Benjamin Rubin, Akiko Suzuki, Prabhudas S. Patel, William A. Gahl, Bharat H. Joshi & Raj K. Puri. (2012) Cysteamine Suppresses Invasion, Metastasis and Prolongs Survival by Inhibiting Matrix Metalloproteinases in a Mouse Model of Human Pancreatic Cancer. PLoS ONE 7:4, pages e34437.
Crossref
Alain Bonnardeaux & Daniel G. Bichet. 2012. Brenner and Rector's The Kidney. Brenner and Rector's The Kidney 1584 1625 .
Daniella Magen & Israel Zelikovic. 2012. Pediatric Bone. Pediatric Bone 727 770 .
Guangmang Liu, Yi Wang, Zhisheng Wang, Jingyi Cai, Xingzuo Lv & Anguo Zhou. (2011) Metabolomic studies on the biochemical profile of urine from rats with acute cysteamine supplementation. Metabolomics 7:4, pages 536-541.
Crossref
Guangmang Liu, Yi Wang, Zhisheng Wang, Jingyi Cai, Xingzuo Lv & Anguo Zhou. (2011) Nuclear Magnetic Resonance (NMR)-Based Metabolomic Studies on Urine and Serum Biochemical Profiles after Chronic Cysteamine Supplementation in Rats. Journal of Agricultural and Food Chemistry 59:10, pages 5572-5578.
Crossref
C. Gibrat & F. Cicchetti. (2011) Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:2, pages 380-389.
Crossref
Jongdoo Lim, Jean-Philippe Pellois & Eric E. Simanek. (2010) A retro-inverso TAT-like peptide designed to deliver cysteamine to cells. Bioorganic & Medicinal Chemistry Letters 20:21, pages 6321-6323.
Crossref
Gregory M. Pastores. (2010) Review: Therapeutic approaches for lysosomal storage diseases. Therapeutic Advances in Endocrinology and Metabolism 1:4, pages 177-188.
Crossref
S. Terryn, O. Devuyst & C. Antignac. (2010) Cell therapy for cystinosis. Nephrology Dialysis Transplantation 25:7, pages 2103-2106.
Crossref
Poonam Sansanwal, Benedict Yen, William A. Gahl, Yewei Ma, Lihua Ying, Lee-Jun C. Wong & Minnie M. Sarwal. (2010) Mitochondrial Autophagy Promotes Cellular Injury in Nephropathic Cystinosis. Journal of the American Society of Nephrology 21:2, pages 272-283.
Crossref
Sunita Bava, Rebecca J. Theilmann, Miriam Sach, Susanne J. May, Lawrence R. Frank, John R. Hesselink, Duc Vu & Doris A. Trauner. (2010) Developmental changes in cerebral white matter microstructure in a disorder of lysosomal storage. Cortex 46:2, pages 206-216.
Crossref
John W. Foreman. 2010. Comprehensive Clinical Nephrology. Comprehensive Clinical Nephrology 584 595 .
Poonam Sansanwal, Neeraja Kambham & Minnie M. Sarwal. (2010) Caspase-4 may play a role in loss of proximal tubules and renal injury in nephropathic cystinosis. Pediatric Nephrology 25:1, pages 105-109.
Crossref
John T. Pinto, Tetyana Khomenko, Sandor Szabo, Gordon D. McLaren, Travis T. Denton, Boris F. Krasnikov, Thomas M. Jeitner & Arthur J.L. Cooper. (2009) Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism. Journal of Chromatography B 877:28, pages 3434-3441.
Crossref
Kimberly SyresFrank HarrisonMatthew TadlockJames V. Jester, Jennifer Simpson, Subhojit Roy, Daniel R. SalomonStephanie Cherqui. (2009) Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood 114:12, pages 2542-2552.
Crossref
Takashi Igarashi. 2009. Pediatric Nephrology. Pediatric Nephrology 1039 1067 .
Raymond Quigley. 2009. Pediatric Nephrology. Pediatric Nephrology 979 1003 .
Galina Nesterova & William Gahl. (2008) Nephropathic cystinosis: late complications of a multisystemic disease. Pediatric Nephrology 23:6, pages 863-878.
Crossref
Luana Di Leandro, Bruno Maras, M. Eugenia Schininà, Silvestro Dupré, Ilias Koutris, Florent M. Martin, Philippe Naquet, Franck Galland & Giuseppina Pitari. (2008) Cystamine restores GSTA3 levels in Vanin-1 null mice. Free Radical Biology and Medicine 44:6, pages 1088-1096.
Crossref
Michael R. Bendel-Stenzel, Julia Steinke, Ranjan Dohil & Youngki Kim. (2007) Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity. Pediatric Nephrology 23:2, pages 311-315.
Crossref
. 2007. Medical Complications of Kidney Transplantation. Medical Complications of Kidney Transplantation 131 164 .
A. M. Das, S. Illsinger & J. H. H. Ehrich. (2006) Lysosomale TransportdefekteLysosomal transport defects. Monatsschrift Kinderheilkunde 154:10, pages 971-977.
Crossref
Robert Kleta. (2006) A deeper look into cysteamine absorption for the treatment of cystinosis. The Journal of Pediatrics 148:6, pages 718-719.
Crossref
Ranjan Dohil, Meredith Fidler, Bruce A. Barshop, Jon Gangoiti, Reena Deutsch, Michael Martin & Jerry A. Schneider. (2006) Understanding intestinal cysteamine bitartrate absorption. The Journal of Pediatrics 148:6, pages 764-769.
Crossref
B.S. Szwergold. (2006) α-Thiolamines such as cysteine and cysteamine act as effective transglycating agents due to formation of irreversible thiazolidine derivatives. Medical Hypotheses 66:4, pages 698-707.
Crossref
Giulio F. Paciotti, David G.I. Kingston & Lawrence Tamarkin. (2006) Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Development Research 67:1, pages 47-54.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.